Table 2. Characteristics of patients treated with sorafenib for patients with hepatocellular carcinoma after resection.
| Authors | Year | Region | Sample | Median Age | Males (%) | Hepatitis status (HBV/non-HBV) | Mean tumor Size (cm) | AFP(≧400 / < 400 ng/mL) | Cirrhosis(%) |
|---|---|---|---|---|---|---|---|---|---|
| Bingfeng Chen | 2016 | China | 24 | 48.00 | 91.67% | – | – | - | 62.5% |
| Jiang Li | 2016 | China | 12 | 49.80 | 100.00% | 3/9 | 9.8 | 8/4 | 0 |
| Lei Zhuang | 2014 | China | 27 | 48.19 | 92.59% | 23/4 | 7.84 | 15/12 | 22.2% |
| Shen-Nien Wang | 2014 | China | 14 | 61.43 | 92.86% | 10/4 | 6.26 | 16/16(≧20/< 20 ng/mL) | 0 |
| Wei Zhang | 2014 | China | 32 | 54.00 | 78.13% | 28/4 | 5.7 | – | – |
| Range | 2014–2016 | China | 12–32 | 48.00–61.43 | 78.13%–100.00% | 3–28/4–9 | 5.7–9.8 | 8–16/4–16 | 0–62.5 |
HBV: hepatitis B virus